Application of lipid in prediction of immune reconstruction result after anti-retrovirus treatment of HIV infected person

By constructing a model based on specific lipid combinations, predicting the immune reconstruction results after antiretroviral treatment in HIV-infected patients, the problem of poor immune reconstruction after treatment is solved, and the prediction accuracy and optimization of treatment plans are improved.

CN118983095APending Publication Date: 2024-11-19THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL

Patent Information

Application Number
CN202411049750.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

After existing antiretroviral treatment, 15% to 30% of HIV-1 infected people fail to recover CD4 T cell counts, resulting in poor immune reconstruction, increasing the risk of AIDS-related diseases and non-AIDS-related events, and its mechanism is unclear .

Method used

A lipid combination is adopted, including LPC16:1, LPC16:0, FFA20:4, PE38:7(16:1_22:6), GM3 d18:1/22:0, TAG53:3(19:1), TAG54 :7(22:6), TAG56:7(22:6), construct a model to predict immune reconstruction results in HIV-infected patients, and verify the model effectiveness through LASSO regression analysis and classifier.

Benefits of technology

Effectively distinguishing between immune responders and immune non-responders, improving prediction accuracy, providing a reference for intervening in the treatment process of immune non-responders, and optimizing the treatment plan for HIV-infected people.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118983095A_ABST
    Figure CN118983095A_ABST
Patent Text Reader

Abstract

The invention discloses a lipid composition and application thereof in constructing a model for predicting an immune reconstruction result of an HIV infected person after anti-retrovirus treatment. According to the present invention, the lipid combination capable of accurately distinguishing the immune responder from the immune non-responder is firstly found, the lipid combination comprises LPC16: 1, LPC16: 0, FFA20: 4, PE38: 7 (16: 122: 6), GM3d18: 1 / 22: 0, TAG53: 3 (19: 1), TAG54: 7 (22: 6) and TAG56: 7 (22: 6), and whether the subject is the immune non-responder can be distinguished by detecting the content of the lipid combination of the subject and constructing the model, such that the disease progress after the HIV infected person is subjected to the anti-retrovirus treatment can be well intervened, and the anti-retrovirus treatment can be easily performed. And the treatment scheme of the HIV infected person is guided and optimized according to the treatment reaction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of clinical medicine, and in particular to the application of lipids in predicting immune reconstruction results of HIV-infected patients after antiretroviral therapy. Background Art

[0002] HIV refers to human immunodeficiency virus. Common HIV viruses are divided into HIV-1 and HIV-2. Currently, the main prevalent strain in my country is HIV-1. After being infected with HIV, it will stimulate the body to cause an immune response. During the acute infection period, the "window period", usually 1-3 weeks after infection, the human body will have transient infectious mononucleosis-like symptoms; then it will enter a clinical latent period of 10 years or more, during which time HIV will kill CD4 T cells and destroy the immune system; the late stage is the AIDS stage, and the patient is extremely susceptible to disease infection, and the final result is death. Since the spread of HIV began, 85.6 million people (64.8 million-113 million people) have been infected with the virus worldwide, and 40.4 million people (32.9 million-51.3 million people) have died from AIDS-related diseases. Because HIV has long destroyed the immune system in the human body, a consensus has been reached at home and abroad: HIV infection should be detected and diagnosed as early as possible, and effective treatment should be carried out as early as possible. The most commonly used treatment method at present is antiretroviral therapy (ART). ART treatment, also known as "cocktail therapy", is a treatment for patients using three or more antiviral drugs in combination. The application of this treatment can reduce the drug resistance caused by single drug use, and inhibit HIV virus replication to the maximum extent, thereby delaying the progression of the disease, prolonging the patient's life, and improving the patient's quality of life.

[0003] However, even though ART treatment has been successful in maximizing long-term suppression of HIV viral replication, 15% to 30% of people infected with HIV-1 (PLWH) still fail to restore their CD4 T cell counts, i.e., poor immune reconstitution. These people are called immune non-responders (INR). Compared with immune responders (IR), immune non-responders have a significantly increased risk of AIDS-related diseases and non-AIDS-related events due to their immune dysfunction, and their risk of death is also increased accordingly. The mechanism of immune non-responder formation is still unclear, and may be related to the patient's age, the time of starting ART treatment, the CD4 T cell count before ART treatment, the level of inflammation, and immune activation. Therefore, early detection of whether HIV-infected people have an immune response after ART treatment will improve subsequent treatment plans and the quality of life of infected people.

[0004] Based on the above background, the present invention proposes a model that can accurately predict the outcome of immune reconstruction in HIV-infected patients after ART treatment, providing a reference for better intervention in the treatment process of immune non-responders, and providing evidence for the effects of HIV infection and ART treatment on human immune and metabolic disorders. Summary of the invention

[0005] In order to make up for the deficiencies of the prior art, the present invention aims to predict the results of immune reconstruction in HIV-infected individuals after receiving antiretroviral therapy.

[0006] In order to achieve the above object, the present invention adopts the following technical solution:

[0007] The first aspect of the present invention provides a lipid combination, which includes LPC16:1, LPC16:0, FFA20:4, PE38:7 (16:1_22:6), GM3 d18:1 / 22:0, TAG53:3 (19:1), TAG54:7 (22:6), and TAG56:7 (22:6).

[0008] In the present invention, the name of the lipid is named according to the well-known lipid abbreviation naming rules, usually in the form of Latin letter abbreviations, such as TAG for triacylglycerol, FFA for free fatty acids, LPC for lysophosphatidylcholine, PE for phosphatidylethanolamine, etc. In the chemical structure of lipids, fatty acids are an important type of component, usually represented by the structure of R-COOH, where R represents the carbon chain. In the abbreviation naming, fatty acids are usually represented by Cn:m, where n represents the number of carbon atoms in the carbon chain, and m represents the degree of unsaturation. For example, C16:0 represents a fatty acid containing 16 carbon atoms and no unsaturated bonds. In a specific embodiment of the present invention, LPC16:1 is a lysophosphatidylcholine containing 16 carbon atoms and 1 unsaturated bond.

[0009] The second aspect of the present invention provides a method for constructing a model for predicting the immune reconstitution results of HIV-infected patients after antiretroviral treatment, the method comprising constructing a model using the lipid combination described in the first aspect of the present invention.

[0010] Furthermore, the method described herein specifically comprises the following steps: obtaining lipid combination content data of immune responders and immune non-responders after antiretroviral treatment according to the first aspect of the present invention, and constructing a model based on the content data.

[0011] Furthermore, the method also includes verifying the model effectiveness.

[0012] In the present invention, the term "immune non-responders" is also called "immune incomplete reconstitution", which refers to HIV-infected people who have achieved long-term suppression of HIV-1 viral replication after antiretroviral treatment, but whose CD4 T cell levels have not recovered to the optimal level. The risk of opportunistic infections, malignant tumors and non-AIDS complications in immune non-responders or people with incomplete immune reconstitution is greatly increased compared with immune responders.

[0013] Furthermore, the method for constructing the model includes but is not limited to classifier and regression analysis.

[0014] The present invention provides a method for constructing a model for predicting the immune reconstruction results of HIV-infected patients after receiving antiretroviral therapy, using a combination of eight key lipids, LPC16:1, LPC16:0, FFA20:4, PE38:7 (16:1-22:6), GM3d18:1 / 22:0, TAG53:3 (19:1), TAG54:7 (22:6), and TAG56:7 (22:6) to construct the model. As known to those skilled in the art, the steps of associating the content of the lipid combination with the immune reconstruction results can be implemented and realized in different ways. The measured values ​​of the lipid combination content are mathematically combined, and the combined lipid content measured values ​​are associated with the problem of predicting the immune reconstruction results, thereby distinguishing IR from INR populations. The measured values ​​of the lipid content can be reasonably combined by any suitable prior art, such as at least one of the algorithms such as classifiers and regression models.

[0015] In a specific embodiment of the present invention, the least absolute shrinkage and selection operator (LASSO) with cross validation is used to select the lipid subset that best distinguishes INR and IR. LASSO regression analysis is called the least absolute shrinkage and selection operator, which refers to a data mining method that adds a penalty function to the commonly used multiple linear regression and continuously compresses the coefficients to streamline the model. It can avoid collinearity and overfitting, solve the problem of screening variables, and can efficiently screen more variables with a smaller sample size.

[0016] Furthermore, the validation efficiency is achieved by plotting the ROC curve and the area under the curve to demonstrate the classification ability of the established model.

[0017] In the present invention, "ROC curve" refers to a tool for evaluating the performance of a classifier. Samples are sorted according to the prediction results of the learner, and the samples are predicted one by one as positive examples in this order. The true positive rate (TPR) and the false positive rate (FPR) are calculated, and the ROC curve is obtained by plotting with TPR as the ordinate and FPR as the abscissa. AUC is the area under the ROC curve, which measures the performance of the model regardless of the threshold. A classifier with a higher AUC has the ability to classify more accurately between two target groups.

[0018] The third aspect of the present invention provides a model constructed based on the method described in the second aspect of the present invention, which is used to predict the outcome of immune reconstitution in HIV-infected individuals after antiretroviral treatment.

[0019] A fourth aspect of the present invention provides a system / device for predicting the immune reconstitution outcome of HIV-infected individuals after antiretroviral therapy, the system / device comprising a classification module;

[0020] Classification module: Based on the model constructed by the lipid combination described in the first aspect of the present invention, the classification result of whether the subject is an immune responder or an immune non-responder is calculated.

[0021] Furthermore, the model constructed based on the lipid combination described in the first aspect of the present invention is a model constructed based on the method described in the second aspect of the present invention.

[0022] Furthermore, the system / device further comprises an input module and an output module, and both the input module and the output module are connected to the classification module;

[0023] Input module: used to input the content data of the lipid combination described in the first aspect of the present invention;

[0024] Output module: used to output classification results.

[0025] The present invention provides a system or device programmed to implement the method of the present invention. The system can be an electronic device of a user or a computer system remotely located relative to the electronic device. The electronic device can be a mobile electronic device. In addition to directly inputting the content data of the lipid combination into the input module of the present invention, the input method also includes using a portable storage medium, a fixed medium or the Internet to transmit the content data of the lipid combination into the input module of the present invention in some way. The classification results output by the output module include outputting to terminals such as storage media, communication media, displays, printers, etc. The electronic device used in the system or device of the present invention can also be various media that can store data, such as a USB flash drive, a mobile hard disk, a read-only memory (ROM, Read-Only Memory), a random access memory (RAM, Random Access Memory), a disk or an optical disk, or a computer device such as a computer, a server, a mobile phone, and a tablet.

[0026] The fifth aspect of the present invention provides the use of a reagent for detecting the content of the lipid combination described in the first aspect of the present invention in a sample to be tested, the model described in the third aspect of the present invention, and the system / device described in the fourth aspect of the present invention in the preparation of a product for predicting the outcome of immune reconstitution in HIV-infected individuals after antiretroviral treatment.

[0027] In the present invention, "lipidomics" as an important branch of metabolomics is the science of studying lipids and their related structures and functions. It is defined as "a comprehensive description of lipid molecular species and their biological roles, covering factors such as lipid metabolism, functional protein expression and gene regulation."

[0028] In the present invention, the term "targeted lipidomics" refers to a method for extensive analysis and evaluation of a specific class of lipids in different tissues and organisms, which is used for the discovery and quantification of differential lipids and for in-depth research and analysis of subsequent lipid molecular markers. These studies involve the use of mass spectrometry, gas chromatography, high pressure liquid analysis and other techniques to analyze or identify different types of lipids, including neutral lipids, phospholipids, triglycerides and cholesterol.

[0029] Furthermore, the reagents include reagents for detecting lipid composition content and sample pretreatment reagents.

[0030] Further, the reagents for detecting the lipid combination content include but are not limited to reagents used for detecting the lipid combination content by any one or more methods of thin layer chromatography, gas chromatography, capillary electrophoresis, supercritical fluid chromatography, and high performance liquid chromatography;

[0031] Furthermore, the sample pretreatment reagents include but are not limited to reagents used to process samples by any one or more of chloroform-methanol extraction, liquid-liquid extraction, solid phase extraction, microwave-assisted extraction, ultrasound-assisted extraction, and supercritical fluid extraction.

[0032] In the present invention, the term "sample pretreatment" refers to the enrichment, extraction and derivatization of the sample to facilitate the subsequent detection of lipid compounds.

[0033] Commonly used lipid extraction techniques mainly include chloroform-methanol extraction, liquid-liquid extraction (LLE) and solid phase extraction (SPE). Since LLE can extract a more comprehensive range of lipid molecules, it is suitable for non-targeted whole lipid analysis; the SPE process allows the sample to undergo separation and enrichment steps to further remove interfering substances and increase the concentration of the analyte, making it more suitable for targeted metabolomics analysis of one or several types of lipid molecules. In recent years, in addition to the above methods, many other methods have also been used in lipidomics sample pretreatment, such as microwave-assisted extraction (MAE), ultrasound-assisted extraction (UAE), supercritical fluid extraction (SFE), etc.

[0034] During the detection process, lipids extracted from samples may face technical problems such as significant differences in ionization efficiency of different lipid molecules, ion suppression effects, insufficient sensitivity of instruments to low-concentration substances, and difficulties in qualitative and quantitative analysis due to the presence of isomers. Therefore, as one of the effective means to solve the above problems, choosing appropriate derivatization treatment in lipidomics analysis is a feasible strategy. Based on conventional mass spectra, commonly used methods include derivatization reactions for lipid double bonds and derivatization reactions for diagnosing lipid polar head groups.

[0035] Furthermore, the sample to be tested is a sample containing the lipidome of an HIV-infected person receiving antiretroviral treatment.

[0036] In the present invention, the term "sample to be tested" refers to a composition obtained from or derived from a subject, which contains cells and / or other molecular entities to be characterized and / or identified based on, for example, physical, biochemical, chemical and / or physiological characteristics. For example, a sample refers to any sample derived from a subject of interest, which is expected or known to contain cells and / or molecular entities to be characterized. Samples include, but are not limited to, tissue samples, primary or cultured cells or cell lines, cell cultures, cell supernatants, cell lysates, platelets, serum, plasma, vitreous humor, lymphatic fluid, synovial fluid, follicular fluid, semen, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, sputum, tears, sweat, mucus, saliva, tissue culture fluid, tissue extracts, homogenized tissues, cell extracts, and combinations thereof.

[0037] In a specific embodiment of the present invention, the sample is plasma.

[0038] Advantages and beneficial effects of the present invention:

[0039] The present invention classifies HIV-infected people into immune responders and immune non-responders according to the results of immune reconstruction after antiretroviral treatment through targeted lipidomics research. Based on the results of lipidomics and LASSO regression analysis, a combination of 8 lipids is proposed, which can effectively predict the results of immune reconstruction of HIV-1 infected people after ART treatment, so as to better intervene in the treatment process of HIV-infected people after antiretroviral treatment, and guide the optimization of HIV-infected people's treatment plan according to the treatment response. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 The lipid spectra in HC, TN, IR and INR, where A is the PLS-DA score graph of lipids in HC, TN, IR and INR, and B is the collection graph of different lipids in HC, TN, IR and INR;

[0041] Figure 2 Volcano plot of differential lipids between IR and INR;

[0042] Figure 3 This is the correlation analysis diagram of IR and INR lipid differences;

[0043] Figure 4 Figure 2 is a graph of the LASSO model and ROC curve, where A is the binomial deviance of the LASSO regression model for differential lipids between IR and INR, B is the coefficient of the LASSO regression model for differential lipids between IR and INR, and C is the ROC curve, showing the model performance evaluated using randomized cross-validation;

[0044] Figure 5 Figure 2 shows the difference in lipid content. DETAILED DESCRIPTION

[0045] The present invention quantitatively detects the lipidomics of immune responders (IR) and immune non-responders (INR) by targeted lipidomics analysis, analyzes the differential lipids in the two groups by LASSO regression model, and draws ROC curve to verify the classification efficiency. After analysis, 8 key lipids were found, namely LPC16:1, LPC16:0, FFA20:4, PE38:7 (16:1-22:6), GM3 d18:1 / 22:0, TAG53:3 (19:1), TAG54:7 (22:6), TAG56:7 (22:6), and the classification AUC of this lipid combination was 0.853, showing that the model provided by the present invention can significantly and effectively distinguish IR and INR.

[0046] The present invention will be further described in detail below in conjunction with the accompanying drawings and examples. The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Simple improvements to the present invention made according to the essence of the present invention all fall within the scope of protection claimed in the present invention.

[0047] Example 1 Targeted lipidomics and bioinformatics analysis

[0048] 1. Experimental Materials and Procedures

[0049] 1. Experimental samples

[0050] The study cohort consisted of 108 participants, including 24 TNs and 68 PLWH receiving ART (33 IRs and 35 INRs). IR was defined as plasma HIV-1 viral load <20 copies / ml and CD4 T-cell count >350 cells / μl after receiving ART for more than 2 years, and INR was defined as CD4 T-cell count ≤350 cells / μl after receiving ART for more than 2 years and plasma HIV-1 viral load <20 copies / ml. Exclusion criteria included pregnancy, any abnormal blood sugar, renal or liver function, or coinfection with hepatitis, tuberculosis, syphilis or other infectious diseases. In addition, 16 HIV-negative HCs were recruited. The characteristics of the participants are shown in Table 1. This study was approved by the Ethics Committee of the Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army (ky-2021-7-6-1) and was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent before enrollment.

[0051] Table 1. Clinical characteristics of participants at enrollment

[0052]

[0053]

[0054] Quantitative variables are expressed as median (range). Qualitative variables are expressed as percentage.

[0055] Abbreviations: HC, healthy controls; TNs, treatment-naive HIV-1-infected persons; IRs, immune responders; INRs, immune nonresponders; BMI, body mass index; NA, not available; LDL, below the limit of detection; ART, antiretroviral therapy; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, nonnucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; T N Cell, naive T cell; T EM Cells, effector memory T cells.

[0056] a Kruskal-Wallis test;b χ2 test; c Mann-Whitney U test.

[0057] As shown in Table 1, there were no statistical differences in gender and BMI among HC, TN, IR, and INR. In addition, there were no statistical differences in ART regimen and duration between IR and INR. Consistent with previous studies, INR patients were older, had lower CD4 T cell counts, and had lower CD4 / CD8 ratios compared with IR. N The frequency of CD4 T cells decreased, while EM Cells and CD8 T EM Compared with HC, T N HLA-DR + CD38 + CD8 T cells and PD-1 + The frequency of CD8 T cells increased significantly. Even in IR, CD8 T cell counts were significantly higher than those in HC. Therefore, ART failed to fully restore the normal immune profile of PLWH, especially in INR, and new intervention targets are needed to achieve better immune recovery.

[0058] 2. Plasma lipidomics extraction

[0059] Lipids were extracted from 20 μL of plasma using a modified version of the Bligh and Dyer method. 750 μL of chloroform:methanol:ultrapure water (3:6:1) (v / v / v) was added to the plasma sample and incubated at 1500 rpm for 1 h at 4°C. At the end of the incubation, 350 μL of deionized water and 250 μL of chloroform were added to induce phase separation. The sample was then centrifuged and the lower organic phase containing lipids was extracted into a clean tube. The lipid extraction was repeated once by adding 450 μL of chloroform to the remaining aqueous phase, and the lipid extracts were combined into one tube and dried in a SpeedVac vacuum concentrator in OH mode. The samples were stored at -80°C until further analysis.

[0060] 3. Quantitative analysis

[0061] Lipidomic analysis was performed using ExionLC AD coupled with Sciex QTRAP 6500PLUS. Individual lipid classes of polar lipids were separated by normal phase (NP)-HPLC using a TUP-HB silica column (150 x 2.1 mm inner diameter, 3 μm) under the following conditions: mobile phase A (chloroform: methanol: ammonium hydroxide, 89.5:10:0.5) and mobile phase B (chloroform: methane: ammonium hydroxide: water, 55:39:0.5:5.5). MRM transitions were established for comparative analysis of various polar lipids. Individual lipid species were quantified by reference to spiked internal standards. d9-PC 32:0 (16:0 / 16:0), d9-PC 36:1p (18:0p / 18:1), d7-PE33:1 (15:0 / 18:1), d9-PE36:1p (18:0p / 18:1), d 31 -PS(d 31 -16:0 / 18:1), d7-PA33:1(15:0 / 18:1), d7-PG33:1(15:0 / 18:1), d7-PI33:1(15:0 / 18:1), C 14 -BMP, d3-16:0 Carnitine, Cer(d18:1 / 15:0-d7), d9-SM d18:1 / 18:1, C8-GluCer, d3-LacCer d18:1 / 16:0, Gb3 d18:1 / 17:0, d7-LPC 18:1, d7-LPE 18:1, C 17 -LPI, C 17 -LPA, C 17 -LPS, C 17 -LPG, d17:1Sph, and d17:1S1P were purchased from Avanti PolarLipids. GM3-d18:1 / 18:0-d3 was purchased from Matreya LLC. 31Free fatty acids were quantified using d-16:0 (Sigma-Aldrich) and d8-20:4 (Cayman Chemicals). Glycerolipids, including diacylglycerols (DAGs) and triacylglycerols (TAGs), were quantified using a modified version of reversed-phase HPLC / MRM. Neutral lipids were separated on a Phenomenex Kinetex-C18 column (4.6 x 100 mm id, 2.6 μm) using an isocratic mobile phase containing chloroform:methanol:0.1 M ammonium acetate (100:100:4) (v / v / v) at a flow rate of 300 μL for 10 min. The levels of short-chain, medium-chain, and long-chain TAGs were calculated with reference to the spiked internal standards obtained for TAG(14:0)3-d5, TAG(16:0)3-d5, and TAG(18:0)3-d5 (CDN isotopes), respectively. DAGs were quantified using d5-DAG 16:0 / 16:0 and d5-DAG 18:1 / 18:1 as internal standards (Avanti Polar Lipids). Free cholesterol and cholesterol esters were analyzed in atmospheric pressure chemical ionization (APCI) mode on an Agilent 1260LC coupled to a Sciex QTRAP 5500 using d6 cholesterol and d6-C18:0 cholesterol ester (CE) (CDNisotopes) as internal standards as described previously. 512 lipids were unambiguously detected and quality control analyses were performed.

[0062] 4. Bioinformatics and statistical analysis

[0063] The characteristics of the enrolled participants were analyzed descriptively using frequency tables of categorical variables and medians and interquartile ranges for continuous variables. Differences in sociodemographic and clinical characteristics between HC, TN, IR, and INR were assessed by chi-square tests to determine the independence of categorical variables. For continuous variables, we used the nonparametric Mann-Whitney U test for comparisons between two groups and the Kruskal-Wallis test for comparisons involving more than two groups.

[0064] Statistical analysis of lipidomics data was performed in R version 4.2.3. Differential analysis was performed using the Limma R package, with age, sex, and BMI as covariates for log2-transformed lipidomics data. P values ​​were adjusted using the Benjamini-Hochberg method. Log2 fold changes and P values ​​from the Limma model were shown as volcano plots for comparison of combined changes. Figure 2 The “UpSetR” package was used to generate a collection plot to visually represent the intersections between statistically significant lipids (Limma P value < 0.05) in various comparison combinations. Figure 1B. Partial least squares discriminant analysis (PLS-DA) was performed using the "ropls" R package, and the clustering of the samples was visualized. The results are shown in Figure 1 A. The least absolute shrinkage and selection operator (LASSO) with cross validation was used to select the lipid subset that best discriminated between INR and IR.

[0065] 5. Lipid combination verification classification efficiency

[0066] ROC curves were plotted using the area under the curve to demonstrate the discriminative ability of the variables selected by LASSO. Networks were constructed from the differentially correlated lipid pairs (P < 0.05) and further analyzed using the R package “MEGENA” (multiscale embedded gene co-expression network analysis), and differential correlations were calculated using the R package DGCA to investigate the core regulation of metabolites that were disturbed between IRs and INRs (P < 0.05). The results are shown in Figure 3 As shown. Module I is centered on methionine sulfoxide and connected to numerous short-chain TAGs (C46-C50) through red lines (- / +), indicating that the negative correlation in IRs becomes positive in INRs. Module II is centered on indole lactic acid and extends to multiple DHA-containing lipids through purple lines (+ / -) and blue lines (0 / -), reflecting the negative core correlation between indole lactic acid and these DHA lipids, which only appears in INRs.

[0067] 2. Model and Verification Results

[0068] Using the LASSO regression model with 6-fold cross validation on all samples, plasma lipids that can distinguish INR and IR were screened out. According to the area under the ROC curve (AUC), 8 lipids were screened out from 52 differential lipids (see Table 2), including LPC16:1, LPC16:0, FFA20:4, PE38:7 (16:1_22:6), GM3 d18:1 / 22:0, TAG53:3 (19:1), TAG54:7 (22:6), and TAG56:7 (22:6). The research cohort was divided into a training set and a test set in a ratio of 7:3. The ROC curve of the model constructed by the combination of 8 lipids showed that the AUC was 0.853, indicating that the prediction results of the model constructed by the lipid combination provided by the present invention are extremely accurate. The results are as follows: Figure 4 The contents of these eight lipids in samples from different groups are shown in Figure 5 As shown, there are significant differences between IR and INR.

[0069] Table 2. Differential lipid profiles between INR and IR

[0070]

[0071]

[0072] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. A lipid combination, comprising LPC16:1, LPC16:0, FFA20:4, PE38:7 (16:1_22:6), GM3 d18:1 / 22:0, TAG53:3 (19:1), TAG54:7 (22:6), and TAG56:7 (22:6).

2. A method for constructing a model for predicting the outcome of immune reconstitution in HIV-infected individuals after antiretroviral therapy, characterized in that: The method comprises constructing a model using the lipid combination of claim 1.

3. The method according to claim 2, characterized in that The specific steps are as follows: obtaining the lipid combination content data of claim 1 for immune responders and immune non-responders after receiving antiretroviral treatment, and constructing a model based on the content data; Preferably, the method further comprises verifying the model effectiveness.

4. The method according to claim 3, characterized in that The method for constructing the model includes but is not limited to classifier and regression analysis.

5. A model constructed based on the method described in any one of claims 2-4.

6. A system / device for predicting the outcome of immune reconstitution in HIV-infected individuals after antiretroviral therapy, characterized in that: The system / device includes a classification module; Classification module: based on the model constructed by the lipid combination of claim 1, calculating and obtaining the classification result of whether the subject is an immune responder or an immune non-responder; Preferably, the model constructed based on the lipid combination of claim 1 is a model constructed based on the method of any one of claims 2-4.

7. The system / device according to claim 6, characterized in that: The system / device further comprises an input module and an output module, wherein the input module and the output module are both connected to the classification module; Input module: used to input the content data of the lipid combination according to claim 1; Output module: used to output classification results.

8. Use of a reagent for detecting the content of the lipid combination described in claim 1 in a sample to be tested, a model described in claim 5, or a system / device described in any one of claims 6 to 7 in the preparation of a product for predicting the outcome of immune reconstitution in HIV-infected individuals after antiretroviral therapy.

9. The use according to claim 8, characterized in that: The reagents include reagents for detecting lipid composition content and sample pretreatment reagents. Preferably, the reagents for detecting the lipid combination content include but are not limited to reagents used for detecting the lipid combination content by any one or more methods of thin layer chromatography, gas chromatography, capillary electrophoresis, supercritical fluid chromatography, and high performance liquid chromatography; Preferably, the sample pretreatment reagents include, but are not limited to, reagents used to process samples by any one or more of chloroform-methanol extraction, liquid-liquid extraction, solid phase extraction, microwave-assisted extraction, ultrasound-assisted extraction, and supercritical fluid extraction.

10. The use according to claim 8, characterized in that: The sample to be tested is a sample containing the lipid group of HIV-infected persons receiving antiretroviral treatment; Preferably, the sample to be tested is plasma.

Citation Information

Patent Citations

  • Application of novel biomarker in predicting progression development of HIV-1-infected patients

    CN110029193A

  • Immune reconstruction result prediction model for HIV / AIDS patient receiving antiretroviral therapy and establishment method thereof

    CN115497622A

  • Lipid biomarker set for representing liver lipid homeostasis imbalance and application

    CN118090989A

  • Method for detection of autoimmune diseases

    US20110275085A1

  • Biomarkers for assessing HIV

    US20170160246A1

Cited By

  • Method and kit for evaluating risk of incomplete immune reconstruction of HIV infected person based on plasma MIG, NGF and GZMB combination

    CN121964156A